Literature DB >> 33628977

Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran.

Maral Gharaghani1, Marzieh Halvaeezadeh1,2, Gholam Ali Jalaee3, Simin Taghipour2, Neda Kiasat2, Ali Zarei Mahmoudabadi1,2.   

Abstract

BACKGROUND AND
PURPOSE: Otomycosis is a secondary ear fungal infection among predisposed individuals in humid conditions. Aspergillus species are the most common etiologic agents of this infection. Several ototopical antifungals are currently used for the treatment of this disease; however, recurrence and treatment failure are usually observed in some cases. Regarding this, the present study was conducted to investigate the antifungal activity of caspofungin, azoles, and terbinafine against the isolated agents of otomycosis.
MATERIALS AND METHODS: This study was conducted on the specimens collected from 90 patients with otomycosis. The samples were cultured on Sabouraud dextrose agar and identified based on morphological characteristics, physiological tests, and microscopic features. Furthermore, the microdilution method was used for antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. Finally, the minimum inhibitory concentration (MIC) and minimum effective concentration (MEC) ranges, MIC/MEC50, MIC/MEC90, and geometric mean (GM) MIC/MEC were calculated for the isolates.
RESULTS: According to the results, 77 patients with otomycosis were positive for different Aspergillus (88.3%) and Candida (11.7%) species. Aspergillus niger complex (n=36) was found to be the most common agent, followed by A. flavus, A. terreus, and A. nidulans complexes. Furthermore, epidemiological cutoff values (ECVs) were lower than those presented by the CLSI for itraconazole and caspofungin in 98.5% and 42.6% of Aspergillus species, respectively. Terbinafine exhibited a great activity against Aspergillus species, while fluconazole revealed a low activity against both Aspergillus species. Based on the results, 77.8% of Candida species were resistant to caspofungin; however, miconazole and econazole had low MIC ranges.
CONCLUSION: Aspergillus niger and A. flavus complexes were identified as the most common agents accounting for 85.7% of the isolates. In addition, terbinafine was identified as the best antifungal for both Aspergillus and Candida species. Moreover, tested azoles had relatively low MICs, whereas most of the isolates had the MIC values beyond the caspofungin ECVs. Copyright:
© 2020, Published by Mazandaran University of Medical Sciences on behalf of Iranian Society of Medical Mycology and Invasive Fungi Research Center.

Entities:  

Keywords:  Antifungals; Caspofungin; Otomycosis; Aspergillus species

Year:  2020        PMID: 33628977      PMCID: PMC7888522          DOI: 10.18502/CMM.6.2.2696

Source DB:  PubMed          Journal:  Curr Med Mycol        ISSN: 2423-3420


  30 in total

1.  Treatment outcome of otomycosis in Ilorin, Nigeria.

Authors:  F E Ologe; C Nwabuisi
Journal:  West Afr J Med       Date:  2002 Jan-Mar

2.  Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).

Authors:  A Espinel-Ingroff; D J Diekema; A Fothergill; E Johnson; T Pelaez; M A Pfaller; M G Rinaldi; E Canton; J Turnidge
Journal:  J Clin Microbiol       Date:  2010-06-30       Impact factor: 5.948

3.  Successful treatment of a recurrent Aspergillus niger otomycosis with local application of voriconazole.

Authors:  M Chappe; S Vrignaud; L de Gentile; G Legrand; F Lagarce; Y Le Govic
Journal:  J Mycol Med       Date:  2018-04-16       Impact factor: 2.391

4.  Otomycosis in Shanghai: aetiology, clinical features and therapy.

Authors:  Xianhao Jia; Qin Liang; Fanglu Chi; Wenjun Cao
Journal:  Mycoses       Date:  2011-10-17       Impact factor: 4.377

5.  Species assignment and antifungal susceptibilities of black aspergilli recovered from otomycosis cases in Iran.

Authors:  Gyöngyi Szigeti; Ebrahim Sedaghati; Ali Zarei Mahmoudabadi; Ali Naseri; Sándor Kocsubé; Csaba Vágvölgyi; János Varga
Journal:  Mycoses       Date:  2011-09-07       Impact factor: 4.377

6.  Otomycosis: clinical features and treatment implications.

Authors:  Tang Ho; Jeffrey T Vrabec; Donald Yoo; Newton J Coker
Journal:  Otolaryngol Head Neck Surg       Date:  2006-11       Impact factor: 3.497

7.  Comparison of caspofungin and amphotericin B for invasive candidiasis.

Authors:  Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

8.  Fungal infections of the ear in immunocompromised host: a review.

Authors:  Borlingegowda Viswanatha; Khaja Naseeruddin
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-01-14       Impact factor: 2.576

9.  Otomycosis in Adolescent Patients Referred to the Therapeutic Centers in Babol City, Iran.

Authors:  Keivan Kiakojuri; Ramazan Rajabnia; Bahareh Jalili; Soraya Khafri; Saeid Mahdavi Omran
Journal:  Jundishapur J Microbiol       Date:  2015-05-31       Impact factor: 0.747

10.  A search for new otomycotic species and their sensitivity to different antifungals.

Authors:  Mohammed Rifaat Ahmed; Ashraf Saad Abou-Halawa; Waheed F Hessam; Diaa' Salaheldin Aly Abdelkader
Journal:  Interv Med Appl Sci       Date:  2018-09
View more
  1 in total

1.  Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.

Authors:  Keyvan Kiakojuri; Saeid Mahdavi Omran; Somayeh Roodgari; Mojtaba Taghizadeh Armaki; Mohammad Taghi Hedayati; Tahereh Shokohi; Iman Haghani; Javad Javidnia; Firoozeh Kermani; Hamid Badali; Mahdi Abastabar
Journal:  Mycopathologia       Date:  2021-03-15       Impact factor: 2.574

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.